Details of the Drug

General Information of Drug (ID: DM0ASTP)

Drug Name

Verapamil

Synonyms

VERAPAMIL; Iproveratril; 52-53-9; Vasolan; Dilacoran; Isoptin; Falicard; Isoptine; Isoptimo; Finoptin; Calan; Verapamilo; Verapamilum; Verapamilum [INN-Latin]; Lekoptin; Verapamilo [INN-Spanish]; Isotopin; Calcan; Tarka; D-365; Securon; Verelan; Izoptin; Verapamil [USAN:INN:BAN]; CP-16533-1; Covera-HS; Verpamil; CCRIS 6749; Verelan PM; Isoptin SR; C; Verapamil

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[2]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

454.6

Topological Polar Surface Area (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The apparent oral clearance of drug is 1007 mL/min [3]
Elimination: Approximately 70% of an administered dose is excreted as metabolites in the urine and more than 16% in the feces within 5 days [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.8 - 7.4 hours [4]
Metabolism: The drug is metabolized via the liver [5]
Vd: The volume of distribution (Vd) of drug is 300 L [6]

Chemical Identifiers

Formula: C27H38N2O4
IUPAC Name: 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
Canonical SMILES: CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
InChI: InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
InChIKey: SGTNSNPWRIOYBX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2520
ChEBI ID: CHEBI:77733
CAS Number: 52-53-9
DrugBank ID: DB00661
TTD ID: D06ECJ
ACDINA ID: D00726

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN two pore channel subtype 2 (TPC2)	TTHQJ2Y	TPC2_HUMAN	Blocker	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 071881.
2	ClinicalTrials.gov (NCT04351763) Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms. U.S. National Institutes of Health.
3	Busse D, Fromm MF, Morike K, Drescher S, Kuhlkamp V, Eichelbaum M: Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. Clin Pharmacol Ther. 2001 May;69(5):324-32. doi: 10.1067/mcp.2001.115125.
4	Verapamil FDA Label
5	Rodriguez-Gascon A, Canut-Blasco A: Deciphering pharmacokinetics and pharmacodynamics of fosfomycin. Rev Esp Quimioter. 2019 May;32 Suppl 1:19-24.
6	Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x.
7	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.